CELLINK and Ossiform look to capitalize on synergies and bring to the market a highly functional bioink for bone-based research. The partnership has scope for additional materials, including.
Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK s bioprinting solutions and Carcinotech s expertise in producing 3D bioprinted living tumors to.
CELLINK, a global leader in 3D bioprinting technologies, is pleased to announce the signing of a distribution agreement with AXT, a prominent player within the scientific equipment landscape in.